Gilead Sciences (GILD) Cash from Financing Activities (2009 - 2026)

Gilead Sciences (GILD) has reported Cash from Financing Activities for 18 consecutive years, with $2.3 billion the latest figure, recorded in Q2 2026.

• For the quarter ending Q2 2026, Cash from Financing Activities rose 249.59% year-over-year to $2.3 billion; the trailing twelve-month figure through Jun 2026 stood at -$4.6 billion (down 13.01% YoY), and the FY2025 full-year result was -$7.7 billion, down 125.6% from the prior year.
• Cash from Financing Activities rose to $2.3 billion in Q2 2026 per GILD's latest filing, from -$4.2 billion in the prior quarter.
• Across five years, Cash from Financing Activities topped out at $2.3 billion in Q2 2026 and bottomed at -$4.2 billion in Q1 2026.
• Historically, Cash from Financing Activities has averaged -$1.4 billion across 5 years, with a median of -$1.4 billion in 2023.
• The widest YoY moves for Cash from Financing Activities: up 305.64% in 2024, down 168.21% in 2024.
• Over 5 years, Cash from Financing Activities stood at -$1.6 billion in 2022, then climbed by 29.28% to -$1.1 billion in 2023, then surged by 305.64% to $2.3 billion in 2024, then tumbled by 155.88% to -$1.3 billion in 2025, then soared by 285.59% to $2.3 billion in 2026.
• According to Business Quant data, Cash from Financing Activities over the past three periods registered $2.3 billion, -$4.2 billion, and -$1.3 billion for Q2 2026, Q1 2026, and Q4 2025 respectively.